Table 2.

Stratification analysis for the association between LMO1 gene polymorphisms and neuroblastoma susceptibility (combined subjects)

Variables	rs2168101 G>T				rs3750952 G>C				Protective genotypes a
	GG	GT/TT	Adjusted OR b	P b	GG	GC/CC	Adjusted OR b	P b	0-1	2-5	Adjusted OR b	P b
	(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)
Age, month
≤18	77/158	47/147	0.65 (0.43-1.00)	0.052	64/146	60/159	0.86 (0.57-1.31)	0.477	58/118	66/187	0.72 (0.47-1.09)	0.123
>18	168/249	81/258	0.46 (0.34-0.64)	<0.0001	148/227	101/280	0.55 (0.40-0.75)	0.0001	126/189	123/318	0.58 (0.43-0.79)	0.0005
Gender
Females	107/166	50/176	0.44 (0.30-0.66)	<0.0001	88/152	69/190	0.63 (0.43-0.92)	0.018	81/127	76/215	0.56 (0.38-0.81)	0.003
Males	138/241	78/229	0.60 (0.43-0.83)	0.002	124/221	92/249	0.66 (0.48-0.92)	0.013	103/180	113/290	0.68 (0.49-0.94)	0.021
Sites of origin
Adrenal gland	95/407	39/405	0.41 (0.28-0.61)	<0.0001	77/373	57/439	0.63 (0.43-0.91)	0.013	63/307	71/505	0.68 (0.47-0.99)	0.044
Retroperitoneal	53/407	34/405	0.65 (0.41-1.02)	0.063	43/373	44/439	0.88 (0.56-1.37)	0.566	38/307	49/505	0.79 (0.51-1.24)	0.300
Mediastinum	74/407	35/405	0.48 (0.31-0.73)	0.0006	71/373	38/439	0.46 (0.30-0.69)	0.0002	67/307	42/505	0.38 (0.25-0.58)	<0.0001
Others	21/407	14/405	0.67 (0.34-1.34)	0.259	18/373	17/439	0.81 (0.41-1.59)	0.535	14/307	21/505	0.91 (0.46-1.82)	0.796
Clinical stages
I+II+4s	103/407	61/405	0.60 (0.42-0.84)	0.003	90/373	74/439	0.70 (0.50-0.98)	0.036	81/307	83/505	0.62 (0.44-0.87)	0.006
III+IV	127/407	62/405	0.48 (0.35-0.68)	<0.0001	110/373	79/439	0.60 (0.44-0.83)	0.002	91/307	98/505	0.65 (0.47-0.89)	0.008

OR, odds ratio; CI, confidence interval.

^a Protective genotypes that decreased neuroblastoma risk were rs2168101 GT/TT, rs1042359 AG/GG, rs11041838 GG, rs2071458 CA/AA, and rs3750952 GC/CC.

^b Adjusted for age and gender, omitting the corresponding stratification factor.